Solid Tumors
Conditions
Interventions
Index test:DOTA-FAPI-04
Sponsors
The Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-75 years old, male and female, with ECoG score of 0 or 1; 2. Subjects with head and neck tumor, lung cancer, esophageal cancer, breast cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, gastric cancer, pancreatic cancer, melanoma, solid tumor of bone or soft tissue sarcoma or suspected tumor who are to undergo pathological biopsy or tumor surgical treatment in the near future (within 2 months); 3. Patients with expected survival >= 12 weeks; 4. Patients whose blood routine and liver and kidney function meet the following criteria: blood routine: WBC >= 4.0 x 10^9/L or neutrophil >= 1.5 x 10^9/L, PLT >= 100 x 10^9 / L, Hb >= 90g / L; PT or APTT <= 1.5 ULN; liver and kidney function: T-Bil <= 1.5 ULT (upper limit of normal value), ALT / AST <= 2.5 ULN or <= 5 ULT (liver metastasis subjects), ALP <= 2.5 ULN (if there is bone metastasis or liver metastasis, ALP <= 4.5 ULN), bun <= 1.5 ULT, SCR <= 1.5 ULT; 5. Patients with at least one measurable target lesion according to recist 1.1; 6. Women must take effective contraceptive measures during the study period and within 6 months after the end of the study (effective contraceptive measures refer to sterilization, hormone device in the child's office, condom, contraceptive / agent, abstinence or partner's vasectomy, etc.); men should agree to take contraceptive measures during the study period and within 6 months after the end of the study period; 7. Patients who can understand and voluntarily sign informed consent and have good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients with severe abnormal liver and kidney functions; 2. Pregnant, pregnant and lactating women; 3. Patients who can't lie flat for half an hour; 4. Patients who refused to join the clinical study; 5. Patients with claustrophobia or other mental diseases; 6. Other researchers think it is not suitable to participate in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax;SEN, SPE, ACC, AUC of ROC; | — |
Countries
China
Contacts
Public ContactYue Chen
The Affiliated Hospital of Southwest Medical University
Outcome results
None listed